A Systematic Review on Clinical Research and Approval Process
DOI:
https://doi.org/10.22270/ajprd.v11i1.1225Keywords:
Drug discovery, Target identification, Target validationAbstract
Drug discovery is a key step or process by which lead molecule is been optimized for further preclinical and clinical trial studies. Drug development process involves target identification, target validation, lead identification, and lead optimization. Once the lead molecule is optimized the HIT compound is been analyzed further in preclinical trial in animals and clinical trial in human subjects. The development of a new drug till marketing authorization should gone through several stages in order to make the drug safe, effective and should posses best quality to get approve for applicable regulatory requirements. The overall theme of our article is to review and state the process from drug discovery to approval for marketing of drug. The process from drug discovery till marketing authorization is time taking, complex and expensive so each target should be consider for development of new drug and new research tools must be used for any new drug development process. It takes around 10-15 years and US$ 1 billion for a new lead compound to make it as a medicine and to get marketing approval for general public use. On an average million lead molecules are been scrutinized to make a HIT compound, so that it can be use for further preclinical and clinical studies to make it available in market. This article provides a brief outline on stages from drug development to clinical research.
Downloads
References
2. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target. Drug Discovery Today, 2012; 17:S24-S30.
3. Terstappen G, Schlüpen, C, Raggiaschi R, Gaviraghi G. Target deconvolution strategies in drug discovery. Nature Reviews Drug Discovery, 2007; 6(11):891-903.
4. Odilia Osakwe. Social Aspects of Drug Discovery, Development and Commercialization. Chapter 6 Preclinical In Vitro Studies: Development and Applicability. Elsevier. 2016.
5. Shana JS, Alan RB, Rex EF, Julia Hoeng, Robert JK, Kristin Schirmer, Maurice Whelan, Martin FW, Manuel CP. Systems Toxicology: From Basic Research to Risk Assessment, 2014; 27(3):314–329.
6. Patidar AK, Selvam G, Jeyakandan M, Mobiya AK, Bagherwal A, Sanadya G, Mehta R. Lead Discovery and lead optimization: A useful strategy in molecular modification of lead compound in analog design. International journal of drug design and discovery. 2011; 2(2):458-463.
7. Dibyajyoti Saha, Milan Hait. Lead Optimization: Research Pathways in Medicinal Chemistry. Asian Journal of Research in Chemistry, 2011; 4(4):509-510.
8. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics, 2003; 151-185.
9. Strickland J, Clippinger AJ, Brown J, Allen D, Jacobs A, Matheson J, Lowit A, Reinke EN, Johnson MS, Quinn MJ Jr, Mattie D, Fitzpatrick SC, Ahir S, Kleinstreuer N, Casey W. Status of acute systemic toxicity testing requirements and data uses by U.S. regulatory agencies. Regul Toxicol Pharmacol. 2018; 94:183-196.
10. Sekimoto K, Tobe M, Saito S. Local anesthetic toxicity: acute and chronic management. Acute Med Surg. 2017 6;4(2):152-160.
11. Bohm R, Proksch E, Schwarz T, Cascorbi I. Drug Hypersensitivity. Dtsch Arztebl Int. 2018; 23;115(29-30):501-512.
12. Phillips DH, Arlt VM. Genotoxicity: damage to DNA and its consequences. EXS. 2009; 99:87-110.
13. Cogliano VJ, Baan RA, Straif K, Grosse Y, Secretan MB, El Ghissassi F, Kleihues P. The science and practice of carcinogen identification and evaluation. Environ Health Perspect. 2004; 112(13):1269-74.
14. Polson AG, Fuji RN. The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell-surface-targeted biological agents in patients. Br J Pharmacol. 2012; 166(5):1600-2.
15. Jackson WM, Gray CD, Jiang D, Schaefer ML, Connor C, Mintz CD. Molecular Mechanisms of Anesthetic Neurotoxicity: A Review of the Current Literature. J Neurosurg Anesthesiol. 2016; 28(4):361-372.
16. Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. Postgrad Med. 2011; 123(5):194-204.
17. Park YR, Yoon YJ, Koo H, Yoo S, Choi CM, Beck SH, Kim TW. Utilization of a Clinical Trial Management System for the Whole Clinical Trial Process as an Integrated Database: System Development. J Med Internet Res. 2018; 24;20(4):e103.
18. Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, Roqué i Figuls M, Parker LA, Caylà J, Bonfill Cosp X. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2016: 17;2016(5):CD009913.
19. El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R. Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist. 2011; 16(9):1292-8.
20. Van Norman GA. Phase II Trials in Drug Development and Adaptive Trial Design. JACC Basic Transl Sci. 2019; 24;4(3):428-437.
21. Follmann D, Proschan M. Two Stage Designs for Phase III Trials. medRxiv [Preprint]. 2020; 31:2020.07.29.20164525.
22. Zhang X, Zhang Y, Ye X, Guo X, Zhang T, He J. Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry. BMJ Open. 2016; 23;6(11):e010643.
23. Evans S, Pocock S. Societal responsibilities of clinical trial sponsors. Lack of commercial pay off is not a legitimate reason for stopping a trial. BMJ. 2001; 10;322(7286):569-70.
24. Baer AR, Devine S, Beardmore CD, Catalano R. Clinical investigator responsibilities. J Oncol Pract. 2011; 7(2):124-8.
25. Sanmukhani J, Tripathi CB. Ethics in clinical research: the Indian perspective. Indian J Pharm Sci. 2011; 73(2):125-30.
26. Shah K. A day in the life of a monitor! Perspect Clin Res. 2012; 3(1):32-4.
27. Buchanan DA, Goldstein J, Pfalzer AC, Lin YC, Kang H, Claassen DO. Empowering the Clinical Research Coordinator in Academic Medical Centers. Mayo Clin Proc Innov Qual Outcomes. 2020; 25;5(2):265-273.
28. Gogtay NJ, Ravi R, Thatte UM. Regulatory requirements for clinical trials in India: What academicians need to know. Indian J Anaesth. 2017; 61(3):192-199.
29. Ciolino JD, Spino C, Ambrosius WT, Khalatbari S, Cayetano SM, Lapidus JA, Nietert PJ, Oster RA, Perkins SM, Pollock BH, Pomann GM, Price LL, Rice TW, Tosteson TD, Lindsell CJ, Spratt H. Guidance for biostatisticians on their essential contributions to clinical and translational research protocol review. J Clin Transl Sci. 2021; 12;5(1):e161.
30. Krishnankutty B, Bellary S, Kumar NB, Moodahadu LS. Data management in clinical research: An overview. Indian J Pharmacol. 2012; 44(2):168-72.
31. Resnik DB, Ness E. Participants' responsibilities in clinical research. J Med Ethics. 2012; 38(12):746-50.
32. Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun. 2018; 7; 11:156-164.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.